替加环素对耐碳青酶烯类抗生素肺炎克雷伯杆菌感染临床治疗的研究进展  

Research Advances on Clinical Therapy of Tigecycline in Infectous Patients Caused by Carbapene-resistant Klebsiella Pneumoniae

作　　者：谢凤[1] 刘晓峰[1] 汤静 XIE Feng;LIU Xiao-Feng;TANG Jing(Shenzhen Nanshan District Maternal and Child Health Hospital,Shenzhen Guangdong 518052,China;Obstetrics and Gynecology Hospital Affiliated to Fudan University,Shanghai 200080,China)

机构地区：[1]深圳市南山区妇幼保健院,广东深圳518052 [2]上海市复旦大学附属妇产科医院,上海200080

出　　处：《抗感染药学》2018年第6期925-931,共7页Anti-infection Pharmacy

摘　　要：耐碳青酶烯类抗生素肺炎克雷伯杆菌(carbapenem-resistant Klebsiella pneumoniae,CRKP)是一种多重耐药的革兰阴性杆菌,病死率较高,已成为院内感染患者死亡的独立危险因素。替加环素是治疗CRKP的主要抗菌药物,其临床使用十分有限,且其单药疗效并不理想,类似耐药报道有所上升。综述CRKP的感染现状及耐药机制文献,分析了替加环素在治疗CRKP中的临床使用情况,提示联合用药疗效要优于单药疗效,且易出现替加环素耐药菌株;最后总结了替加环素耐药的具体机制及相关的预防措施,以期为临床治疗CRKP提供一定参考依据。Carbapenem-resistant Klebsiella pneumoniae（CRKP） is a multidrug-resistant gram-negative bacillus,with high fatality rate, and has become an independent risk factor for the death of patients in hospital. Tigecycline is the main antibiotics for the treatment of CRKP. It has limited clinical application, and its single drug efficacy is not satisfied, and the drug resistance reporting is also increasing. The literatures on the infection status and drug resistance mechanism of CRKP were reviewed. The infection status, drug resistance mechanism of CRKP and the progress of study on the clinical application of ticarycline in the treatment of CRKP were briefly discussed. It is suggested that the antibiotic combination therapy is superior to the monotherapy, and the drug resistant strain is easy to appear. Finally, the specific mechanism and preventive measures for the drug resistance are summarized so as provide some reference for the clinical treatment of CRKP.

关 键 词：替加环素 耐碳青霉烯类肺炎克雷伯杆菌 肺炎克雷伯菌碳青霉烯酶 

分 类 号：R965[医药卫生—药理学]